InVivo Therapeutics Holdings Corp. (NVIV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.19+0.02 (+0.28%)
At close: 4:00 PM EDT
People also watch:
AVXLCURONCSADXSCTIX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open7.29
Prev Close7.17
Bid6.50 x 2000
Ask8.85 x 700
Day's Range7.00 - 7.35
52wk Range3.50 - 11.80
1y Target EstN/A
Market Cap229.56M
P/E Ratio (ttm)-10.91
Beta3.55
Volume251,925
Avg Vol (3m)222,685
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research4 days ago

    NVIV: 5th Patient Conversion Supports Target Price Increase

    On August 17, 2016, InVivo Therapeutics Holdings Corp. (NVIV) announced that patient number nine had converted from a complete AIS A to an incomplete AIS B spinal cord injury in between the second and third month evaluations.  This marks the fifth patient to improve at least one AIS grade of eight patients that are currently enrolled in the study.  As a result of achieving this milestone, we increase the probability of ultimate FDA approval from 65% to 75% and increase our target price from $16.00 per share to $18.00 per share. To assess probable benefit, InVivo along with the FDA established the objective performance criteria (OPC) in February of this year.  The OPC was set at 25% or more of the patients in the INSPIRE study achieving an improvement of at least one AIS grade by six months post-implantation.

  • TheStreet.com8 days ago

    These 7 Stocks Under $10 Could Make You a Lot of Money

    When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

  • TheStreet.com9 days ago

    Vonage Is Starting to Look Technically Attractive

    It is starting to poke its head above key resistance.